A Phase IIb/III, Multi-Center, Randomized, Parallel Group, Controlled Study to Evaluate the Efficacy and Safety of 750 mg and 1000 mg of LLL-3348 of Lupin Limited in Moderate to Severe Chronic Stable Plaque Type of Psoriasis.

Trial Profile

A Phase IIb/III, Multi-Center, Randomized, Parallel Group, Controlled Study to Evaluate the Efficacy and Safety of 750 mg and 1000 mg of LLL-3348 of Lupin Limited in Moderate to Severe Chronic Stable Plaque Type of Psoriasis.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 02 Sep 2016

At a glance

  • Drugs LLL 3348 (Primary) ; Methotrexate
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Sponsors Lupin
  • Most Recent Events

    • 11 Dec 2013 Status changed from active, no longer recruiting to completed as reported by Clinical Trials Registry - India.
    • 28 Aug 2010 Status changed from recruiting to active, no longer recruiting as reported by Clinical Trials Registry - India record.
    • 09 Feb 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top